nach oben

Erschienen in:

28.05.2021 | Original Article

Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores

verfasst von: Seyed Reza Najafizadeh, Khatereh Amiri, Maryam Moghaddassi, Shaghayegh Khanmohammadi, Hossein Mirmiranpour, Manouchehr Nakhjavani

Erschienen in: Clinical Rheumatology | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Rheumatoid arthritis (RA) is a prevalent inflammatory disorder causing functional disabilities. Oxidative stress can cause inflammation and can also be induced by inflammation. Measuring oxidative stress markers could help better understand the pathophysiology of RA and may be used to define the disease severity.

Material and method

In this case–control study, 75 RA patients were selected among those referred to the rheumatology clinic. Patients were further categorized into two groups, with active and inactive disease according to the Disease Activity Score (DAS) 28. Forty healthy volunteered persons were selected as the control group. Blood samples were obtained, and advanced glycation end products (AGEs), advanced oxidation protein products (AOPPs), and ferric reducing ability of plasma (FRAP) were measured. The results were compared via student t-test and Chi-square.

Results

Mean ± SD values for AGEs, AOPP, and FRAP in cases and controls were 53.29 ± 6.82 vs. 44.43 ± 7.13 (p = 0.001), 146.08 ± 19.56 vs. 135.79 ± 14.23 (p = 0.004), and 967.13 ± 226.66 vs. 1012.87 ± 215.94 (p = 0.2), respectively. Mean ± SD values for AGEs, AOPP, and FRAP in patients with active disease and inactive disease were 53.32 ± 7.2 vs. 53.26 ± 6.48 (p = 0.9), 146.97 ± 17.56 vs. 145.06 ± 21.84 (p = 0.6), and 953.17 ± 217.09 vs. 983.09 ± 239.31 (p = 0.5), respectively.

Conclusion

AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls. There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease.

Key points

• AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls.

• There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease

Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3):S265-272. https://doi.org/10.1186/ar578CrossRefPubMedPubMedCentral

Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, National Arthritis Data W (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58(1):15–25. https://doi.org/10.1002/art.23177CrossRefPubMed

Myasoedova E, Davis J, Matteson EL, Crowson CS (2020) Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann Rheum Dis 79(4):440–444. https://doi.org/10.1136/annrheumdis-2019-216694CrossRefPubMed

Wu X, He B, Liu J, Feng H, Ma Y, Li D, Guo B, Liang C, Dang L, Wang L, Tian J, Zhu H, Xiao L, Lu C, Lu A, Zhang G (2016) Molecular insight into gut microbiota and rheumatoid arthritis. Int J Mol Sci 17(3):431. https://doi.org/10.3390/ijms17030431CrossRefPubMedPubMedCentral

Gibofsky A (2012) Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 18(13 Suppl):S295-302PubMed

van Vollenhoven RF (2009) Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med 7:12. https://doi.org/10.1186/1741-7015-7-12CrossRefPubMedPubMedCentral

Lin L, Zhang J (2017) Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol 18(1):2. https://doi.org/10.1186/s12865-016-0187-3CrossRefPubMedPubMedCentral

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://doi.org/10.1002/art.27584CrossRefPubMed

Villeneuve E, Nam J, Emery P (2010) 2010 ACR-EULAR classification criteria for rheumatoid arthritis. Rev Bras Reumatol 50(5):481–483CrossRefPubMed

10.

Di Lorenzo G, Minciullo PL, Leto-Barone MS, La Piana S, La Porta G, Saija A, Gangemi S (2013) Differences in the behavior of advanced glycation end products and advanced oxidation protein products in patients with allergic rhinitis. J Investig Allergol Clin Immunol 23(2):101–106PubMed

11.

Veselinovic M, Barudzic N, Vuletic M, Zivkovic V, Tomic-Lucic A, Djuric D, Jakovljevic V (2014) Oxidative stress in rheumatoid arthritis patients: relationship to diseases activity. Mol Cell Biochem 391(1–2):225–232. https://doi.org/10.1007/s11010-014-2006-6CrossRefPubMed

12.

Jaswal S, Mehta HC, Sood AK, Kaur J (2003) Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338(1–2):123–129. https://doi.org/10.1016/j.cccn.2003.08.011CrossRefPubMed

13.

Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M (2009) Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 48(10):1190–1196. https://doi.org/10.1093/rheumatology/kep199CrossRef

14.

Prasad K (2014) Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol 23(1):11–16. https://doi.org/10.1055/s-0033-1363423CrossRefPubMedPubMedCentral

15.

Rodriguez-Garcia J, Requena JR, Rodriguez-Segade S (1998) Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem 44(2):250–255CrossRefPubMed

16.

Esteghamati A, Eskandari D, Mirmiranpour H, Noshad S, Mousavizadeh M, Hedayati M, Nakhjavani M (2013) Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr 32(2):179–185. https://doi.org/10.1016/j.clnu.2012.08.006CrossRefPubMed

17.

García-González A, Gaxiola-Robles R, Zenteno-Savín T (2015) Oxidative stress in patients with rheumatoid arthritis. Rev Investig Clin 67(1):46–53

18.

Mititelu RR, Pădureanu R, Băcănoiu M, Pădureanu V, Docea AO, Calina D, Barbulescu AL, Buga AM (2020) Inflammatory and oxidative stress markers-mirror tools in rheumatoid arthritis. Biomedicines 8(5):125. https://doi.org/10.3390/biomedicines8050125CrossRefPubMedCentral

19.

Bassu S, Zinellu A, Sotgia S, Mangoni AA, Floris A, Farina G, Passiu G, Carru C, Erre GL (2020) Oxidative stress biomarkers and peripheral endothelial dysfunction in rheumatoid arthritis: a monocentric cross-sectional case-control study. Molecules 25 (17). https://doi.org/10.3390/molecules25173855

20.

Quiñonez-Flores CM, González-Chávez SA, Del Río ND, Pacheco-Tena C (2016) Oxidative stress relevance in the pathogenesis of the rheumatoid arthritis: a systematic review. Biomed Res Int 2016:6097417. https://doi.org/10.1155/2016/6097417CrossRefPubMedPubMedCentral

21.

Martu M-A, Surlin P, Lazar L, Maftei GA, Luchian I, Gheorghe D-N, Rezus E, Toma V, Foia L-G (2021) Evaluation of oxidative stress before and after using laser and photoactivation therapy as adjuvant of non-surgical periodontal treatment in patients with rheumatoid arthritis. Antioxidants (Basel) 10(2):226. https://doi.org/10.3390/antiox10020226CrossRef

22.

23.

Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66(3):407–409. https://doi.org/10.1136/ard.2006.054205CrossRefPubMed

24.

Kalousova M, Skrha J, Zima T (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51(6):597–604PubMed

25.

Benzie IF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 239(1):70–76. https://doi.org/10.1006/abio.1996.0292CrossRefPubMed

26.

Datta S, Kundu S, Ghosh P, De S, Ghosh A, Chatterjee M (2014) Correlation of oxidant status with oxidative tissue damage in patients with rheumatoid arthritis. Clin Rheumatol 33(11):1557–1564. https://doi.org/10.1007/s10067-014-2597-zCrossRefPubMed

27.

Kundu S, Ghosh P, Datta S, Ghosh A, Chattopadhyay S, Chatterjee M (2012) Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. Free Radic Res 46(12):1482–1489. https://doi.org/10.3109/10715762.2012.727991CrossRefPubMed

28.

Stamp LK, Khalilova I, Tarr JM, Senthilmohan R, Turner R, Haigh RC, Winyard PG, Kettle AJ (2012) Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology (Oxford) 51(10):1796–1803. https://doi.org/10.1093/rheumatology/kes193CrossRef

29.

Senolt L, Braun M, Vencovsky J, Sedova L, Pavelka K (2007) Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis. Physiol Res 56(6):771–777PubMed

30.

de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CGM, Bijl M, Posthumus MD (2011) Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res Ther 13(6):R205–R205. https://doi.org/10.1186/ar3538CrossRefPubMedPubMedCentral

31.

Yang X, Chang Y, Wei W (2020) Emerging role of targeting macrophages in rheumatoid arthritis: focus on polarization, metabolism and apoptosis. Cell Prolif 53(7):e12854. https://doi.org/10.1111/cpr.12854CrossRefPubMedPubMedCentral

32.

Jin X, Yao T, Ze Z, Zhu J, Zhang S, Hu W, Shen C (2015) Advanced glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-<i>κ</i>B pathway. Biomed Res Int 2015:732450. https://doi.org/10.1155/2015/732450CrossRefPubMedPubMedCentral

33.

Vytášek R, Šedová L, Vilím V (2010) Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord 11(1):83. https://doi.org/10.1186/1471-2474-11-83CrossRefPubMedPubMedCentral

34.

Ye W, Zhu S, Liao C, Xiao J, Wu Q, Lin Z, Chen J (2017) Advanced oxidation protein products induce apoptosis of human chondrocyte through reactive oxygen species-mediated mitochondrial dysfunction and endoplasmic reticulum stress pathways. Fundam Clin Pharmacol 31(1):64–74. https://doi.org/10.1111/fcp.12229CrossRefPubMed

35.

Benzie IF, Chung WY (1999) Total antioxidant power of plasma: male-female differences and effect of anticoagulant used. Ann Clin Biochem 36(Pt 1):104–106. https://doi.org/10.1177/000456329903600116CrossRefPubMed

36.

Najafizadeh SR, Ghazizadeh Z, Nargesi AA, Mahdavi M, Abtahi S, Mirmiranpour H, Nakhjavani M (2015) Analysis of serum heat shock protein 70 (HSPA1A) concentrations for diagnosis and disease activity monitoring in patients with rheumatoid arthritis. Cell Stress Chaperones 20(3):537–543. https://doi.org/10.1007/s12192-015-0578-zCrossRefPubMedPubMedCentral

Titel: Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores
verfasst von: Seyed Reza Najafizadeh
Khatereh Amiri
Maryam Moghaddassi
Shaghayegh Khanmohammadi
Hossein Mirmiranpour
Manouchehr Nakhjavani
Publikationsdatum: 28.05.2021
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 10/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-021-05771-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores